#	Pagina
attuale pagina	/open-h2020/projects/226398/index.html
-1	/open-h2020/projects/194827/index.html
-2	/open-h2020/per-topic/repatriation/list/index.html
-3	/open-h2020/projects/197883/results.html
-4	/open-h2020/projects/209319/index.html
-5	/open-h2020/projects/205472/results.html
-6	/open-h2020/per-topic/blend/list/index.html
-7	/open-h2020/projects/201377/results.html
-8	/open-h2020/per-topic/encounter/list/index.html
-9	/open-h2020/projects/193462/index.html
-10	/open-h2020/per-topic/conventional/list/index.html

Opendata, web and dolomites

STI-001 SIGNED

Turn Cancer Immunotherapy Effective in Most Patients

Total Cost €

EC-Contrib. €

Partnership

Views

STI-001 project word cloud

Explore the words cloud of the STI-001 project. It provides you a very rough idea of what is the project "STI-001" about.

vlps tumour biological immune stimulator answer restores distant survival company business particle create disruptive named plan public develops strategy checkpoint encapsulates letters metastatic 50 fires tumours cancers durable intent see kill safe leader potent companies 2m rates proprietary sti restore natural private update sting immunotherapy regulatory ligand edge pharmaceutical nevertheless validate stimunity shown 001 date million chemical stimulatory inducing unresponsive anti marketing weakened smei1 inhibitors physicians worldwide cancer tumor genes activate ligands immuno demonstrated vlp therapeutic cells licensing competitors first raised fto innate manufacturing virus beginning confirm weaker pipeline interferon feasibility unseen patients drugs showed cutting larger option

Project "STI-001" data sheet

The following table provides information about the project.

Coordinator	STIMUNITY SAS Organization address address: RUE D'AMSTERDAM 57 city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-12-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STIMUNITY SAS STIMUNITY SAS Organization address address: RUE D'AMSTERDAM 57 city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	50˙000.00

Map

Project objective

Stimunity is a company that develops disruptive immuno-stimulatory biological drugs to restore the immune system against tumor cells. Immune checkpoint inhibitors showed great potential in cancer immunotherapy after achieving 5-year survival rates for patients with advanced or metastatic cancers, unseen by physicians before. This is a promising beginning. Nevertheless, 5 million patients worldwide remain unresponsive to immunotherapy and do not have any other therapeutic option. On average it represents 50% of all cancers. A promising answer to this problem is the development of new drugs that activate the STING (STimulator of INterferon Genes) pathway, which fires up the innate immune system of these unresponsive patients, inducing a potent and durable anti-tumour immune response. It is expected to be effective on a much larger number of cancer patients. Stimunity’s first product, named STI-001, restores weakened immune systems to kill tumour cells. It is especially effective on distant tumours. Competitors using chemical STING ligands have shown a much weaker immune response than STI-001. STI-001 is based on a safe cutting-edge Virus-Like Particle (VLP) technology that encapsulates the best-known natural STING ligand and efficiently deliver it into immune cells. There is high interest in STI-001, as demonstrated by public and private funding (raised €2.2M to date) and advanced discussions with major pharmaceutical companies (see Letters of Intent). SMEi1 project will allow Stimunity to i) confirm the technical feasibility of manufacturing STI-001, (ii) update the FTO, (iii) assess regulatory issues, (iv) validate the marketing and business plan. Our long-term goal is to develop a pipeline of products based on proprietary VLPs in cancer immunotherapy and create a long term out-licensing strategy as a worldwide leader in VLP-based immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STI-001" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STI-001" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.